Hymecromone
- Generic Name
- Hymecromone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H8O3
- CAS Number
- 90-33-5
- Unique Ingredient Identifier
- 3T5NG4Q468
- Indication
用于胆囊炎、胆石症、胆道感染及胆囊术后综合征。
- Associated Conditions
- Biliary Dyskinesia, Dyspepsia, Gallbladder Inflammation, Gallstones, Biliary spasm, Mild, moderate Hepatic Insufficiency
- Associated Therapies
- -
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
Phase 2
Not yet recruiting
- Conditions
- Lung Diseases, InterstitialInterstitial Lung DiseaseIdiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- Target Recruit Count
- 37
- Registration Number
- NCT06325696
- Locations
- 🇺🇸
NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina, United States
Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Aparna Goel
- Target Recruit Count
- 24
- Registration Number
- NCT05295680
- Locations
- 🇺🇸
Stanford Clinic, Stanford, California, United States
A Study of Oral Hymecromone and Hyaluronan Synthesis
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- Paul Bollyky
- Target Recruit Count
- 12
- Registration Number
- NCT02780752
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath